49 completed, 15 terminated, 2 unknown, 2 withdrawn. 33 Phase 2, 21 Phase 1, 11 Phase 3, 4 Not applicable.
Follow Neoplasms, Breast: new trials by email Literature Review of Neoplasms, Breast trials Research Report on Neoplasms, Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors VB15010 - Cancer, Neoplasms | Phase 1 / Phase 2 | Recruiting | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 188 | 2024-10-30 | 2025-02-11 |
| Study of ESG401 in Adults With Solid Tumors ESG401 - Neoplasms, Breast, Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Shanghai Escugen Biotechnology Co., Ltd | 156 | 2021-09-14 | 2025-09-12 |
| Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease Niraparib, Placebo - Neoplasms, Breast | Phase 3 | Active not recruiting | GlaxoSmithKline | 40 | 2021-06-28 | 2025-07-16 |
| Early Rehabilitation for Breast Cancer - A Randomized Control Trial Physical Therapy - Neoplasms, Breast | Not applicable | Terminated | University of South Carolina | 3 | 2021-04-01 | 2023-11-30 |
| Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA Liquid biopsy and CT scan - Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms | Not applicable | Unknown | Centro di Riferimento Oncologico - Aviano | 164 | 2018-05-22 | 2023-04-14 |
| Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer Niraparib - Neoplasms, Breast | Phase 1 | Completed | Tesaro, Inc. | 21 | 2018-04-12 | 2025-01-08 |
| Pre- Versus Postoperative Accelerated Partial Breast Irradiation partial breast irradiation - Breast Cancer, Cancer of the Breast | Not applicable | Terminated | The Netherlands Cancer Institute | 65 | 2016-11-10 | 2022-09-29 |
| Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer Lapatinib, Trastuzumab, Paclitaxel - Neoplasms, Breast | Phase 2 | Unknown | Xijing Hospital | 100 | 2016-07-01 | 2017-09-06 |
| Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs) - Neoplasms, Breast | Phase 2 | Terminated | Novartis Pharmaceuticals | 42 | 2014-10-24 | 2021-10-13 |
| Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients Lapatinib plus capecitabine - Neoplasms, Breast | Completed | GlaxoSmithKline | 1 | 2014-08-01 | 2015-08-10 | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients niraparib, Physician's choice - Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Terminated | Tesaro, Inc. | 216 | 2014-02-25 | 2022-11-15 |
| Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer Neoplasms, Breast | Completed | Fuda Cancer Hospital, Guangzhou | 40 | 2014-01-01 | 2015-06-03 | |
| A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA - Neoplasms, Neoplasms, Ovarian | Phase 1 | Completed | Janssen Research & Development, LLC | 54 | 2013-05-01 | 2015-12-04 |
| Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer Neoplasms, Breast | Terminated | GlaxoSmithKline | 117 | 2011-12-01 | 2015-03-09 | |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Eribulin, Doxorubicin, Cyclophosphamide - Breast Neoplasms, Breast Cancer | Phase 2 | Terminated | Emory University | 7 | 2011-11-01 | 2016-10-03 |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer Lapatinib, Trastuzumab, Docetaxel - Neoplasms, Breast | Phase 2 | Withdrawn | GlaxoSmithKline | 2011-10-01 | 2013-03-13 | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Lapatinib, Trastuzumab, Aromatase Inhibitor - Neoplasms, Breast | Phase 3 | Completed | Novartis Pharmaceuticals | 369 | 2011-05-05 | 2025-03-07 |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor - Neoplasms, Breast | Phase 2 | Terminated | GlaxoSmithKline | 66 | 2011-04-11 | 2021-05-25 |
| Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer Lapatinib, Trastuzumab, Epirubicin - Neoplasms, Breast | Phase 2 | Withdrawn | GlaxoSmithKline | 2010-12-01 | 2017-06-07 | |
| Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC Lapatinib in combination with weekly paclitaxel - Neoplasms, Breast | Phase 2 | Completed | GlaxoSmithKline | 12 | 2010-04-01 | 2014-10-07 |
Showing 20 of 71. Sign in to see all of them.
Breast Neoplasms (71) · Neoplasms (7) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5) · Brain Neoplasms (2) · Colorectal Neoplasms (2) · Inflammatory Breast Neoplasms (2) · Osteitis Deformans (2) · Biliary Tract Neoplasms (1) · Breast Diseases (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1) · Stomach Neoplasms (1)
Neoplasms by Site (71) · Skin Diseases (71) · Skin and Connective Tissue Diseases (71) · Breast Diseases (70) · Neoplasms (64) · Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplastic Processes (5)
Lapatinib (48) · Paclitaxel (14) · Trastuzumab (14) · Capecitabine (6) · Cyclophosphamide (5) · Docetaxel (5) · Epirubicin (5) · pazopanib (5) · Doxorubicin (4) · Aromatase Inhibitors (3) · niraparib (3) · Carboplatin (2) · Fluorouracil (2) · Vinorelbine (2) · 10-propargyl-10-deazaaminopterin (1)
GlaxoSmithKline (43) · Novartis Pharmaceuticals (13) · Emory University (2) · Tesaro, Inc. (2) · Acrotech Biopharma Inc. (1) · Centro di Riferimento Oncologico - Aviano (1) · Fuda Cancer Hospital, Guangzhou (1) · Georgetown University (1) · Janssen Research & Development, LLC (1) · Novartis (1) · Shanghai Escugen Biotechnology Co., Ltd (1) · The Netherlands Cancer Institute (1) · University of South Carolina (1) · Xijing Hospital (1) · Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (1)
United States (46) · Italy (22) · Spain (21) · Belgium (19) · Canada (19) · France (19) · United Kingdom (19) · Germany (15) · Russia (14) · Israel (13) · Poland (13) · Peru (12) · South Korea (12) · China (11) · Hungary (11)
Astrid Scholten, MD, PhD (1) · Claudine Isaacs, M.D. (1) · Fabio Puglisi, MD (1) · Fei Ma (1) · Garry Weems, PharmD (1) · Keerthi Gogineni, MD, MSHP (1) · Monica Rizzo, MD (1) · Rui Ling, Doctor (1)
PMID 39613746, PMID 19394894, PMID 20095796, PMID 20179708, PMID 20214527, PMID 21676217, PMID 22257673, PMID 22473314, PMID 22476856, PMID 22785351, PMID 22839200, PMID 23054212, PMID 23234763, PMID 23509322, PMID 23667487, PMID 23878115, PMID 24304724, PMID 24346280, PMID 24395109, PMID 24590635, PMID 24687830, PMID 24800949, PMID 25056500, PMID 25130998, PMID 25752740, PMID 25851628, PMID 26181252, PMID 26245675, PMID 26571496, PMID 26993131, PMID 27140800, PMID 27684533, PMID 28176175, PMID 29156708, PMID 29902299, PMID 31240310, PMID 32203207, PMID 32822287, PMID 33152119, PMID 33765513, PMID 34153715, PMID 34921525, PMID 35610260, PMID 36050448, PMID 39216478, PMID 39418883, PMID 40359710
2005 (3), 2004 (1), 2008 (1), 2014 (1)